GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a parallel-group, multi-center, long-term extension study from the GALLANT 4 study to
monitor the safety and tolerability of oral tesaglitazar compared with glibenclamide in
patients with type 2 diabetes for up to 100 weeks of treatment. The total duration, including
treatment and follow-up, is 103 weeks.